Oligodendroglioma: pathology, molecular mechanisms and markers
about
Fluorescence in situ hybridization in surgical pathology: principles and applications.Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas.Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.A malignant cellular network in gliomas: potential clinical implications.Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas.Minibrain and Wings apart control organ growth and tissue patterning through down-regulation of CapicuaGlioma: experimental models and reality.Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.Molecular mechanisms involved in gliomagenesis.Molecular characterization reveals NF1 deletions and FGFR1-activating mutations in a pediatric spinal oligodendroglioma.A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment.Characterization of gliomas: from morphology to molecules.Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status.Periprostatic venous thrombosis.Vessel morphometric parameters-correlation with histologic grade and VEGF expression in oligodendroglioma.Spinal metastases of two different grade oligodendrogliomas: a case report and review of literature.Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases.MR textural analysis on T2 FLAIR images for the prediction of true oligodendroglioma by the 2016 WHO genetic classification.Clinicopathologic features of small cell glioblastomas.Altered capicua transcriptional repressor gene expression exhibits distinct prognostic value for isocitrate dehydrogenase-mutant oligodendroglial tumors.Conventional and advanced magnetic resonance imaging in patients with high grade glioma.Comparative analysis of histologically classified oligodendrogliomas reveals characteristic molecular differences between subgroups.Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.Identification and targeting of an FGFR fusion in a pediatric thalamic "central oligodendroglioma".Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion.Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma.Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways
P2860
Q33593910-4CF0DE97-CD25-4089-9EDE-B0670F2A362DQ36234884-A5BA3BC4-A71E-42ED-A885-E5990F392AF7Q36569563-215C8891-68FF-48D6-A007-642B98DC5FF6Q36645979-2B7DA3E4-2840-4F33-ACD2-91E3E4880B1DQ36705939-71B94A43-BC80-498A-BE54-65E79E4C6F98Q36819744-BCE895A2-8B44-4DA1-BCD0-854051F61050Q37281524-F9DA123C-CBE7-41B6-9644-2E3B57CF22F6Q37596796-EA30D451-A5D6-4766-BF60-90169922CB96Q37662100-88F69A3D-22D0-4238-BB68-3D741912B9DEQ38766569-B9C97CB2-38D5-439D-85CD-1A0CD150639EQ39174603-38F5605B-4025-4D58-A6DF-A6001BE8ED7AQ39200135-670B1088-DC4B-4C68-AC18-3DFD098B1436Q39412967-CA8FFF1D-3732-4F1F-8C34-A963AD727EF4Q41342863-09F80784-1542-47EB-B922-D671E1465F73Q41629691-FD2E5091-B403-4F3C-823E-425F83EF2752Q42020014-79ED62ED-95C0-412E-B058-E3557C2406A9Q45130102-436FA757-B173-4648-AE55-1A0B0DFDA33EQ47139133-B96A6532-70A4-4D43-A4BF-8A820903466AQ47593121-34654126-F52B-4660-8703-863F08CD9A1BQ49058205-732CA6AF-DC6E-4066-AEDB-F5DD70F3156CQ50045950-8BE5A17B-C4B4-486E-AB02-29607CA317C8Q52562075-B152BCB8-1FFC-42F5-8E4C-28DAA767351BQ52598227-B30655D9-765F-49A6-9B49-9F6B448A9005Q54123926-08BEC1A8-FFAE-443E-9EE4-5DBA507D635DQ55298059-A14C5C26-25D5-4CA4-B9AF-A82EEC8C9CB9Q55338815-E8F3B845-5B8A-4F7B-98C9-5B8C0BF458E4Q55457291-BC4F43BD-8184-4D8A-8A51-8DD71D2F31AEQ58700004-FE14D57B-4393-4511-9B74-F27A094229B5
P2860
Oligodendroglioma: pathology, molecular mechanisms and markers
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Oligodendroglioma: pathology, molecular mechanisms and markers
@ast
Oligodendroglioma: pathology, molecular mechanisms and markers
@en
Oligodendroglioma: pathology, molecular mechanisms and markers
@nl
type
label
Oligodendroglioma: pathology, molecular mechanisms and markers
@ast
Oligodendroglioma: pathology, molecular mechanisms and markers
@en
Oligodendroglioma: pathology, molecular mechanisms and markers
@nl
prefLabel
Oligodendroglioma: pathology, molecular mechanisms and markers
@ast
Oligodendroglioma: pathology, molecular mechanisms and markers
@en
Oligodendroglioma: pathology, molecular mechanisms and markers
@nl
P2860
P921
P3181
P1476
Oligodendroglioma: pathology, molecular mechanisms and markers
@en
P2093
Arie Perry
P2860
P2888
P304
P3181
P356
10.1007/S00401-015-1424-1
P407
P5008
P577
2015-05-06T00:00:00Z
P5875
P6179
1027199189